SCHEMBL324830

SCHEMBL324830

COc1ccc(OC(=O)N2C=Cc3ccccc3C2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
BCHE P06276 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
TAS1R2 Q8TE23 1/20 0.43
NPY2R P49146 1/20 0.40
RAB9A P51151 4/20 0.39
NPC1 O15118 3/20 0.39
TAAR1 Q96RJ0 1/20 0.39
ROCK1 Q13464 1/20 0.39
ALDH1A1 P00352 4/20 0.38
HTT P42858 2/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
PKM P14618 2/20 0.38
MAPK1 P28482 2/20 0.38
USP2 O75604 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL324821 0.89 SMN1; SMN2 (0.55) LIPESMN1; SMN2BCHERAB9ANPC1
SCHEMBL324810 0.84 LIPE (0.44) LIPESMN1; SMN2BCHEALDH1A1HPGD
SCHEMBL324667 0.84 P2RX4 (0.48) SMN1; SMN2TAS1R3TAS1R1TAS1R2RAB9A
SCHEMBL3628702 0.83 P2RX4 (0.46) SMN1; SMN2BCHETAS1R3TAS1R1TAS1R2
SCHEMBL15055276 0.82 MGLL (0.46) ALDH1A1GAACYP2D6
SCHEMBL22411030 0.81 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1ALDH1A1HPGD
SCHEMBL324261 0.78 BCHE (0.46) SMN1; SMN2BCHERAB9ANPC1CASP3
SCHEMBL29493251 0.77 HDAC3 (0.41) SMN1; SMN2BCHERAB9AALDH1A1GAA
SCHEMBL15056964 0.77 HDAC3 (0.41) SMN1; SMN2BCHERAB9AALDH1A1GAA
SCHEMBL325470 0.77 KDM4E (0.44) SMN1; SMN2TAS1R3TAS1R1TAS1R2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 LIPE 1443/4885SMN1; SMN2 4056/4885BCHE 4335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.